Molnupiravir: Merck’s Covid-19 antiviral less effective in new analysis
Updated data on molnupiravir shows the drug reduces hospitalisation or death by 30%, down from the initially reported 50% efficacy.
Pharmaceuticals
Biomanufacturers are facing persistent malware attacks, says cybersecurity group
The cyberattack, named Tardigrade, has been identified at two different biomanufacturing facilities.
Chinese infectious disease venture financing receives a booster from Covid-19
The impact of the Covid-19 pandemic has raised the importance of funding drug development for...
Vaccibody rebrands to Nykode and bags $925m deal with Regeneron
Norwegian vaccine and immunotherapy-focused biopharma Vaccibody has rebranded to Nykode after signing a nearly $1bn...
Aducanumab: will Biogen’s Aduhelm recover from its rocky start?
The US approval of Alzheimer’s drug aducanumab was met with controversy and the resignation of...
Paxlovid: what we know about Pfizer’s Covid-19 pill
Pfizer is seeking emergency use authorisation from the FDA for its novel Covid-19 antiviral pill Paxlovid.
J&J spin-off: pharma continues to cut the cord on consumer healthcare
The move will allow Johnson & Johnson to focus on its pharmaceutical and medical device divisions.
Q&A: Covid-19’s Delta subvariant and the risky winter ahead
Virologist Dr Phillip Gould discusses the Delta subvariant, vaccines, and the new Covid-19 antiviral molnupiravir.
J&J to divide into consumer health and pharmaceutical businesses
The separation is expected to be completed in 18 to 24 months.
Antibiotic resistance: how AI can tackle the superbug threat
Researchers are employing artificial intelligence to combat the growing global threat of antibiotic resistance.
Cervical cancer: real-world data highlights value of HPV vaccine market
A recent study found that the UK’s HPV vaccine programme has dramatically reduced cervical cancer rates in the country.
